Anavex Life Sciences’ Blarcamesine Shows Promise in Parkinson’s Disease Dementia
Anavex Life Sciences has reported promising results from their phase 2 extension study of
ANAVEX2-73, also known as blarcamesine, for Parkinson’s disease dementia (PDD).
Conducted over a 48-week period, the study demonstrated the drug’s potential to
significantly improve clinical symptoms in affected patients.
Despite initial delays due to the COVID-19 pandemic, which resulted in a 41-week pause, the
open-label extension revealed notable improvements. Participants showed
advancements in their Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) scores, with significant changes in both cognitive
function and sleep behavior. These findings suggest that blarcamesine may offer
hope for addressing the urgent unmet needs of patients with Parkinson’s disease.
The study involved 132 participants who were randomized to receive either 30 mg or 50 mg of
blarcamesine or a placebo. During the trial, patients were permitted to
continue their existing anti-Parkinson’s medication regimens, ensuring the
focus remained on assessing the efficacy of blarcamesine. The results indicated
a measurable improvement in MDS-UPDRS scores, with those on higher doses
witnessing the most significant changes.
Anavex Life Sciences is optimistic about the potential of blarcamesine,
underscoring its capability to restore disrupted neurodegenerative gene
expressions. The therapeutic effects observed were supported by significant
biomarker correlations, suggesting a possible pathway towards mitigating the
progression of PDD symptoms.
Although the study was limited by its sample size, the promising outcomes have led to further
exploration under compassionate use provisions. Anavex plans to continue with additional studies to confirm these findings and expand on their
potential applications.
These developments mark an important step forward for Anavex and the medical community in the
ongoing battle against Parkinson’s disease dementia, offering a glimmer of hope
for patients and caregivers alike.
Visit this page on LinkedIn, to learn more.
More about Anavex on https://www.sotcanalytics.com/update-compendium-2024#h.874e6qgoo0o6
